Biotech investment news: Era Biotech, Aura Bioscience, Quirumed and others (March 2015)

Integral service around a transaction
BY : Diego GutiérrezMay Wed, 2015
In March 2015, the biotechnology sector in Spain has been the protagonist of several investment operations, both venture capital and private equity. acquisitions of companies.

health March 2015



Venture capital invests in biotech: Inveready, Ysios

Venture capital investment in biotechnology worldwide has grown considerably in 2014. In the US, biotech has become the second most preferred sector for venture capital after software, growing by 29% in 2014.

In Spain, several operations were also carried out in March. Inveready has taken over the assets of Era BiotechEra Biotech was founded in 2002 and specialised in innovative solutions in vaccines and molecules. Inveready has committed before the commercial judge to take on a team of four professionals, led by Miriam Bastida -one of the company's founders-, and to invest 1.5 million euros in the firm over a period of six years.

"Inveready is betting on biotechnology, in May 2015 the CDTI has injected €5M into the Inveready Innvierte Biotech II fund, which aims to invest in early stage companies that require between 1 and 4 M of investment and whose developments are related to the creation of new drugs, diagnostics and prognostics, and nutraceutical and functional products" says Diego Gutierrez of Abra- Invest.

Ysios Capital has entered the US Aura Biosciences through an €18.8M funding round, in which also participated Chiesi Ventures, Alexandria Venture Investmentsas well as the company's existing partners: Li-Cor Biosciences and Henri Termeer, former CEO of Genzyme.

"This investment is the second by Ysios BioFund II, which two weeks before announcing this round had invested in Switzerland's Prexton Therapeutics. Both are signs of the international orientation of Ysios' investments," says Diego Gutierrez.

Acquisitions in the sector

Grifols buys US-based Alkahest's 45% for €33.3M. Alkahest is a company created in 2014 to advance research conducted by a group of Stanford University scientists who pioneered the idea that a component of the blood of young animals has the ability to restore cognitive abilities in old animals. Alkahest is currently conducting research to see if this model could be transferred to humans.

Suarahas started its international expansion with the acquisition of Serproen Home CareSuara is a Chilean company specialising in home health care. Suara is a Catalan cooperative that offers a range of services, including care homes for the elderly and nursery schools.

With the aim of providing comprehensive care, Suara will complement its activities with home care for dependents and the construction of retirement homes and day centres. 


If you are looking for financing, we can help you, please contact us on +34 946424142.

 Other posts that may interest you

Sendabio with the help of Abra Invest closes investment round

Operations Biotechnology February 2015

The M&A Professionals

Meet our services



Do you want to be up to date?


Our diferentiation

Market Research Technology
Our team of market analysis specialists is continuously analyzing the investments of the most active markets in the industry in order to unceasingly contribute ideas of the current market situation and identify the most relevant trends for senior management. We integrate the most relevant sources of information which allows us to discover the most interesting companies for venture capital and similarly helps us to identify the investors with the highest probability of involvement in an M&A process to ensure the success of our sell-side operations.

The reports and deductions of our advisors provide a broad view of the sector, both geographically and from the complementary or adjacent markets perspective.
Technology Data Analytics
for M&A
Advanced data anlytics is a weapon". Intelfin is an artificial intelligence tool we use for investing and creating value in SMEs through competitive analytics and the enterprise environment.

IntelFin consists of a cognitive system, which, through the application of advanced analytical technologies, facilitates the automation of investment and financing decisions in the field of non-listed companies and especially SMEs in high-growth sectors.

The information related to these companies is characterized by their lack of transparency and heterogeneity; thus, it is necessary to develop an advanced analysis which is as much predictive as prescriptive and is developed in a natural language custom, suitable to obtain greater clarity and knowledge of the investment scope.

The IntelFin system focuses especially on analyzing the variables that define and influence the competitive environment of a sector and the positioning of a company, analyzing their influence on future value creation. Therefore, IntelFin supports strategic decision-making to senior management by resolving questions such as:

¿What are my competitors' priorities, strategies and expansion plans? Who's my competition? Which competitor is most likely to grow at a higher rate?
Which areas of activity/business models will receive the most investment? Which sectors are most attractive to investors?
Which companies are going to experience the most growth in the near future? Which companies are most likely to receive investment or be acquired?
Training Methodology
We have developed training programs in an innovative set-up which guarantees our teams the acquisition of technical competences both in the field of corporate finance and in the field of psychology, that is much needed when it comes to negotiation processes.

We have a culture of continuous improvement of our processes, closely related to the use of information systems that allow the enhancement of internal communication between our teams, as well as external communication with our customers. Hence, we extend best practices identified internally in an efficient and rapid manner among our members.

Are you one of those who prefer to be well informed when making decisions?